Skip to main content
SpringerLink
Log in

The 5-HT1A Receptor: an unkept promise?

  • Chapter
Anxiolytics

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

Stimulation of 5-HTIA receptors appears to be the most plausible basis for the anxiolytic effects of buspirone and has been hypothesized to explain effects of SSRIs in depression and panic disorder [1]. A surprising number of relatively selective agonists have been developed since the introduction of buspirone (Mead Johnson) in 1986 for anxiety. Despite the plethora of preclinical models in which 5-HTIA agonists have produced evidence suggestive of anxiolytic and antidepressant activity, no new compound other than tandospirone (Sumitomo, Pfizer) has been registered. The large number of presentations at meetings, notations in industry media or corporate press releases, and much smaller number of peer reviewed publications on phase II/III studies underway in patients with generalized anxiety disorder or depression give a very mixed picture on these newer agents. Until the recent FDA approval of the antidepressant venlafaxine (Wyeth-Ayrst) (a mixed 5HT and noradrenergic uptake inhibitor at higher doses) for generalized anxiety disorder (GAD), there were no successors to buspirone or the benzodiazepines in the United States or Europe.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. Rasmussen K, Rocco VP (1995) Recent progress in serotonin. In: JA Briston (ed.): Ann Reports in Medicinal Chemistry, Vol 30, Academic Press, New York, 1–9

    Google Scholar 

  2. Enserink M (1999) Can placebo be the cure? Science 284: 238–240

    Article  PubMed  CAS  Google Scholar 

  3. Rausch JL, Stahl SM, Hauger RL (1990) Cortisol and growth hormone responses to the 5-HTIA agonists gepirone in depressed patients. Biol Psychiat 28: 73–78

    Article  PubMed  CAS  Google Scholar 

  4. Fletcher A, Cliffe IA, Dourish CT (1993) Silent 5-HTIA receptor antagonists: utility as research tools and therapeutic agents. Trends Pharmacol Sci 14: 441–448

    Article  CAS  Google Scholar 

  5. DeVry J (1995) 5-HTIA receptor agonists: recent developments and controversial issues. Psychopharmacology 121: 1–26

    Article  CAS  Google Scholar 

  6. Blier P, Curet O, Chaput Y, de Montigny C (1991) Tandospirone and its metabolite, 1-(2-pyrimidil)-piperazine, II: effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission. Neuropharmacology 30: 691–701

    Article  PubMed  CAS  Google Scholar 

  7. Gobbi M, Frittoli E, Mennini T (1990) Antagonist properties of 1-(2-pyrimidil)-piperazine at presynaptic adrenoceptors in the rat brain. Eur J Pharmacol 180: 183–186

    Article  PubMed  CAS  Google Scholar 

  8. Borsini F (1998) Pharmacology of 5-HTIA receptors: critical aspects. CNS Spectrums 3: 17–38

    Google Scholar 

  9. Kenakin T (1987) Agonists, partial agonists, antagonists, inverse agonists and agonist/antagonists? Trends Pharmacol Sci 8: 423–426

    Article  CAS  Google Scholar 

  10. Gartside SE, Cowen PJ (1994) 5-HTIA receptors and antidepressant drug action. In: SA Montgomery and TH Corn (eds): Psycopharmacology of depression. Oxford University Press, Oxford, 66–86

    Google Scholar 

  11. Yocca FD (1990) Neurochemistry and neurophysiology of buspirone and gepirone: interactions at presynaptic and postsynaptic 5-HTIA receptors. J Clin Psychopharmacol 10: 6S–12S

    Article  Google Scholar 

  12. Cleare AJ, Forsling M, Bond AJ (1998) Neuroendocrine and hypothermic effects of 5-HTIA receptor stimulation with ipsapirone in healthy men: a placebo-controlled study. Int Clin Psychopharmacol 13: 23–32

    Article  PubMed  CAS  Google Scholar 

  13. Sargent P, Williamson DJ, Pearson G, Odontiadis J, Cowen PJ (1997) Effect of paroxetine and nefazodone on 5-HTIA receptor sensitivity. Psychopharmacology 132: 296–302

    Article  PubMed  CAS  Google Scholar 

  14. Gammans RE, Stringfellow JC, Hvizdos AJ, Seidehamel RJ, Cohn JB, Wilcox CS, Fabre LF, Pecknold JC, Smith WT, Rickels K (1992) Use of buspirone in patients with generalized anxiety disorder and co-existing depressive symptoms: a meta-analysis of eight randomized, controlled studies. Neuropsychobiology 25: 193–201

    Article  PubMed  CAS  Google Scholar 

  15. Pecknold JC (1994) Serotonin 5-HTIA agonists: a comparative review. CNS Drugs 2: 234–251

    Article  CAS  Google Scholar 

  16. Fulton B, Brogden RN (1997) Buspirone: an updated review of its clinical pharmacology and therapeutic applications. CNS Drugs 7: 68–88

    Article  CAS  Google Scholar 

  17. Apter JT, Allen LA (1999) Buspirone: future directions. J Clin Psychopharmacol 19: 86–93

    Article  PubMed  CAS  Google Scholar 

  18. Griebel G (1997) Serotonergic drugs in animal models of anxiety: an update, Serotonin, vol. 2, no. 6. In: The investigational drugs database [Corporate Intranet]. © 1997–1998 Current Drugs Ltd. [1999, March 2]

    Google Scholar 

  19. IMSWorld Publications Editorial Staff Ipsapirone (pINN) Drug Abstract. In: IMSWorld RandD Focus, [Lotus Notes]. © 1999 IMSWorld Publications Limited. [30 March 1999]

    Google Scholar 

  20. IMSWorld Publications Editorial Staff Gepirone (INN) Drug Abstract. In: IMSWorld RandD Focus, [Lotus Notes]. © 1999 IMSWorld Publications Limited. [30 March 1999]

    Google Scholar 

  21. Drugs Editorial Staff. Gepirone Drug Report In: The Investigational Drugs database, [Lotus Notes]. © 1997–1998 Current Drugs Ltd. [30 March 1999]

    Google Scholar 

  22. Jenkins SW, Robinson DS, Fabre Jr LF, Andary JJ, Messina ME, Reich LA (1990) Gepirone in the treatment of major depression. J Psychopharmacol 10(s): 77–87

    Article  Google Scholar 

  23. Wilcox CS, Ferguson JM, Dale JL, Heiser JF (1996) A double-blind trial of low-and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull 32: 335–342

    PubMed  CAS  Google Scholar 

  24. Feiger AD (1996) A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Psychopharmacol Bull 32: 659–665

    PubMed  CAS  Google Scholar 

  25. McGrath PJ, Stewart JW, Quitkin FM, Wager S, Jenkins SW, Archibald DG, Stringfellow JC, Robinson DS (1994) Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. J Clin Psychopharmacol 14: 347–352

    Article  PubMed  CAS  Google Scholar 

  26. Pecknold JC, Luthe L, Scott Fluery M-H, Jenkins S (1993) Gepirone and the treatment of panic disorder: an open study. J Clin Psychopharmacol 13: 145–149

    Article  PubMed  CAS  Google Scholar 

  27. Rickels K, Schweizer E, DeMartinis N, Mandos L, Mercer C (1997) Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychopharmacol 17: 272–277

    Article  PubMed  CAS  Google Scholar 

  28. Bristol-Myers Squibb (1993) Licensing Information. Company Communication September 10

    Google Scholar 

  29. International Editorial Staff Gepirone (BMY 13805, MJ 13805) Profile In: Adis R and D Insight, [Lotus Notes]. © 1998 Adis International Ltd. [30 March 1999]

    Google Scholar 

  30. PBJ Publications Editorial Staff Pharmaprojects Record No.: 006405. In: PJB Pharmaprojects, [Corporate Intranet]. © 1998 PJB Publications Ltd. [30 March 1999]

    Google Scholar 

  31. Fabre-Kramer gepirone NDA for depression under preparation (1996) FDC Reports Pink Sheet 58: 40 Tand G-10

    Google Scholar 

  32. Drugs Editorial Staff Tandospirone Drug Report. In: The Investigational Drugs database, [Lotus Notes]. © 1997–1998 Current Drugs Ltd. [30 March 1999]

    Google Scholar 

  33. Adis International Editorial Staff Tandospirone (Metanopirone, SM 3997, Sediel) Profile In: Adis R and D Insight, [Lotus Notes]. © 1998 Adis International Ltd. [30 March 1999]

    Google Scholar 

  34. Murasaki M, Mori A, Kudo Y (1993) Efficacy of a new anxiolytic, tandospirone (SM-3997) on neurosis. Neuropsychopharmacology 9 (Suppl): 125

    Google Scholar 

  35. Hadrav V, Blier P, Dennis T, Ortemann C, de Montigny C (1995) Characterization of 5-hydroxytryptamine lA properties of flesinoxan: in vivo electrophysiology and hypothermia study. Neuropharmacology 34: 1311–1326

    Article  Google Scholar 

  36. Seletti B, Bemkelfat C, Blier P, Annable L, Gilbert F, de Montigny C (1995) Serotonin lA receptor activation by flesinoxan in humans: body temperature and neuroendocrine responses. Neuropsychopharmacology 13: 93–104

    Article  PubMed  CAS  Google Scholar 

  37. Bradford LD, Stevens G (1994) Double-blind, placebo controlled fixed dose study of flesinoxan in generalized anxiety disorder. Amer Coll Neuropsychopharmacol 167

    Google Scholar 

  38. van Vliet IM, Westenberg HGM, den Boer JA (1996) Effects of the 5-HTIA receptor agonist flesinoxan in panic disorder. Psychopharmacology 127: 174–180

    Article  PubMed  Google Scholar 

  39. Current Drugs Editorial Staff Zalospirone Drug Report. In: The Investigational Drugs database, [Lotus Notes]. © 1997–1998 Current Drugs Ltd. [14 April 1999]

    Google Scholar 

  40. Rickels K, Derivan A, Kunz N, Pally A, Schweizer E (1996) Zalospirone in major depression: a placebo-controlled multicenter study. J Clin Psyhcopharmacol 16: 212–217

    Article  CAS  Google Scholar 

  41. Adis International Editorial Staff Lesopitron (E 4424) Profile. In: Adis R and D Insight, [Lotus Notes]. © 1998 Adis International Ltd. [30 March 1999]

    Google Scholar 

  42. Current Drugs Editorial Staff Lesopitron Drug Report. In: The Investigational Drugs database, [Lotus Notes]. © 1997–1998 Current Drugs Ltd. [30 March 1999]

    Google Scholar 

  43. Sramek JJ, Fresquet A, Marion-Lanais G, Hourani J, Jhee SS, Martinez L, Jensen CM, Bolles K, Carrington AT, Cutler NR (1996) Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: a bridging study. J Clin Psychopharmacol 16: 454–458

    Article  PubMed  CAS  Google Scholar 

  44. Adis International Editorial Staff MKC 242 Profile In: Adis R and D Insight, [Lotus Notes]. CD 1998 Adis International Ltd. [30 March 1999]

    Google Scholar 

  45. Current Drugs Editorial Staff MKC-242 Drug Report. In: The Investigational Drugs database, [Lotus Notes]. © 1997–1998 Current Drugs Ltd. [30 March 1999]

    Google Scholar 

  46. Adis International Editorial Staff BAY X 3702 (BAY 3702) Profile In: Adis R and D Insight, [Lotus Notes]. © 1998 Adis International Ltd. [30 March 1999]

    Google Scholar 

  47. Current Drugs Editorial Staff Bay-x-3702 Drug Report In: The Investigational Drugs database, [Lotus Notes]. © 1997–1998 Current Drugs Ltd. [30 March 1999]

    Google Scholar 

  48. PBJ Publications Editorial Staff Pharmaprojects Record No.: 008383024493 In: PJB Pharmaprojects, [Corporate Intranet]. © 1998 PJB Publications Ltd. [30 March 1999]

    Google Scholar 

  49. De Vry J, Dietrich H, Glasser T (1997) BAY x 3702. Drugs of the Future 22: 341–349

    Google Scholar 

  50. Adis International Editorial Staff Sunepitron (CP 93393) Profile. In: Adis R and D Insight, [Lotus Notes]. © 1998 Adis International Ltd. [30 March 1999]

    Google Scholar 

  51. Current Drugs Editorial Staff Sunepitron Hydrochloride Drug Report In: The Investigational Drugs database, [Lotus Notes]. © 1997–1998 Current Drugs Ltd. [30 March 1999]

    Google Scholar 

  52. Current Drugs Editorial Staff DU-125530 Drug Report In: The Investigational Drugs database, [Lotus Notes]. © 1997–1998 Current Drugs Ltd. [30 March 1999]

    Google Scholar 

  53. PBJ Publications Editorial Staff Pharmaprojects Record No.: 027926 In: PJB Pharmaprojects, [Corporate Intranet]. © 1998 PJB Publications Ltd. [30 March 1999]

    Google Scholar 

  54. Adis International Editorial Staff S 15535 Profile In: Adis R and D Insight, [Lotus Notes]. © 1998 Adis International Ltd. [1 April 1999]

    Google Scholar 

  55. Current Drugs Editorial Staff S-15535 Drug Report In: The Investigational Drugs database, [Lotus Notes]. © 1997–1998 Current Drugs Ltd. [1 April 1999]

    Google Scholar 

  56. Adis International Editorial Staff Alnespirone (S 20499) Profile In: Adis R and D Insight, [Lotus Notes]. © 1998 Adis International Ltd. [30 March 1999]

    Google Scholar 

  57. Current Drugs Editorial Staff Alnespirone Drug Report In: The Investigational Drugs database, [Lotus Notes]. © 1997–1998 Current Drugs Ltd. [30 March 1999]

    Google Scholar 

  58. Ennis MD (1993) The therapeutic potential of 5-HTIA agonists Curr Opin Invest Drugs 2: 271–279

    Google Scholar 

  59. Heiser JF, Wilcox CS (1998) Serotonin 5-HTIA receptor agonists as antidepressants: pharmacological rationale and evidence for efficacy CNS Drugs 10: 343–353

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Eli Lilly and Company, Lilly Research Laboratories, Lilly Corporate Center DC 1730, Indianapolis, IN 46285, USA

    Louise R. Levine & William Z. Potter

Authors
  1. Louise R. Levine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William Z. Potter
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut de Recherche Pierre Fabre, Parc Industriel de la Chartreuse, Castres, 81100, France

    Mike Briley

  2. Psychopharmacology Unit School of Medical Science, University of Bristol, University Walk, Bristol, BS8 1TD, UK

    David Nutt

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Basel AG

About this chapter

Cite this chapter

Levine, L.R., Potter, W.Z. (2000). The 5-HT1A Receptor: an unkept promise?. In: Briley, M., Nutt, D. (eds) Anxiolytics. Milestones in Drug Therapy. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8470-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8470-9_7

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9581-1

  • Online ISBN: 978-3-0348-8470-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation